Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alaunos Therapeutics (TCRT) Research & Development (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Research & Development for 15 consecutive years, with $471000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Research & Development rose 229.37% year-over-year to $471000.0, compared with a TTM value of $916000.0 through Sep 2025, down 33.72%, and an annual FY2024 reading of $362000.0, down 97.78% over the prior year.
  • Research & Development was $471000.0 for Q3 2025 at Alaunos Therapeutics, up from $184000.0 in the prior quarter.
  • Across five years, Research & Development topped out at $14.5 million in Q3 2021 and bottomed at -$86000.0 in Q4 2024.
  • Average Research & Development over 5 years is $4.9 million, with a median of $5.2 million recorded in 2023.
  • The sharpest move saw Research & Development plummeted 109.22% in 2024, then surged 229.37% in 2025.
  • Year by year, Research & Development stood at $8.2 million in 2021, then plummeted by 31.76% to $5.6 million in 2022, then tumbled by 83.36% to $933000.0 in 2023, then tumbled by 109.22% to -$86000.0 in 2024, then surged by 647.67% to $471000.0 in 2025.
  • Business Quant data shows Research & Development for TCRT at $471000.0 in Q3 2025, $184000.0 in Q2 2025, and $347000.0 in Q1 2025.